source
- Veradermics reports positive Phase 2/3 results for oral Rogaine in men with pattern hair lossVeradermics, a biotech that recently went public, announced that its oral formulation of Rogaine met the primary endpoints in a late-stage Phase 2/3 trial. The study enrolled men with mild-to-mode…
- Revolution Medicines threatens lawsuit against Erasca over RAS drug patent and efficacy claimsEarlier this month a newly announced cancer therapy generated strong interest from patients and investors. The drug, which targets the RAS pathway, was highlighted for its potential impact on oncol…